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Despite advances in the management of solid tumours, the development of metastases continues to be the most significant problem
and cause of death for cancer patients. To define genetic determinants of pulmonary metastases, we have applied oligonucleotide
microarrays to established murine models of highly metastatic D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. These
models are characterised by primary subcutaneous growth in C57BL/6J mice, a period of minimal residual disease and spontaneous
pulmonary metastases. Microarray analysis defined seven genes, namely – arginase, brain natriuretic peptide (BNP), interleukin-1
alpha (IL-1 alpha), plasminogen activator inhibitor-2 (PAI-2), surfactant protein C (SP-C), uteroglobin (UG) and wnt-1-induced
secreted protein-1 (WISP-1), which were consistently elevated in pulmonary metastases compared to the primary tumour of both
D122 and B16-F10.9 models. Previous studies demonstrated that two of these seven genes, IL-1 alpha and PAI-2, are involved in the
metastatic process. The results obtained by the microarrays were confirmed by real-time quantitative PCR, for three chosen genes –
PAI-2, WISP-1 and UG. Our approach aimed to identify genes essential for the metastatic process in general and for pulmonary
metastases specifically. Further research should address the precise role of these genes in the metastasising process to the lungs and
test if they could be used as targets for future therapies.
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A crucial event during cancer progression is the switch from a
locally growing tumour to a metastatic one. Tumour development
and metastasis are complex processes that include transformation,
proliferation, resistance to apoptosis, invasion, neovascularisation
and metastatic spread (Liotta et al, 1991). Studies to identify
molecules involved in tumour development and progression have
resulted in the identification of a number of individual candidates
that function as cell growth factors (Grandis et al, 1998), adhesion
molecules (Van Waes et al, 1991, 1995), proteases (Andreasen et al,
2000), and cytokines that promote inflammation and angiogenesis
(Chen et al, 1998, 1999).
The discovery of these molecules may be useful in develop-
ing new therapeutic interventions. For instance, synthetic
Arg-Gly-Asp (RGD) containing peptides can disrupt integrin
function (e.g., vitronectin receptor) and successfully inhibit
both in vitro and in vivo melanoma cell invasion (Gehlsen et al,
1988).
Metastasis is a multiple-step process in which cancer cells leave
the primary tumour site and relocate in a remote organ. This
process involves interactions between cancer cells and their
surrounding microenvironment. Tumours that metastasise do so
to preferred target organs. To explain this apparent specificity,
over 100 years ago, Paget formulated his ‘seed and soil’ hypothesis;
that is, cells from a given tumour would ‘seed’ only favourable
‘soil’ in a target organ, one that supports colonisation for
metastasis to occur.
Several studies used an in vivo selection scheme to select highly
metastatic cell lines (Clark et al, 2000; Chen et al, 2001; Khanna
et al, 2001). By analysing these cells on microarrays, gene
expression patterns that correlate with progression to a metastatic
phenotype have been defined. Clark et al (2000) have shown that
the small GTPase RhoC enhances metastasis when overexpressed,
whereas a dominant-negative Rho inhibits metastasis. Analysis of
the phenotype of cells expressing dominant-negative Rho or RhoC
indicates that RhoC is important in tumour cell invasion. The
process of selecting highly metastatic cell lines, as done by Clark
et al (2000), resulted in a large number of genes related solely to
metastasis, but not to the microenvironmental changes in the
preferred target organs.
To provide insight into mechanisms that allow tumours to
metastasise specifically to the lungs, we searched for the genes Received 20 September 2002; accepted 18 March 2003
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scoordinately overexpressed in pulmonary metastases of two
distinct metastatic cell lines of different embryonic origin. The
cell lines we used were the highly metastatic mouse D122 Lewis
lung carcinoma and B16-F10.9 melanoma. We hypothesised that
genes overexpressed in pulmonary metastases of both cell lines,
might play a key role in both metastasis and homing of the
metastasising cells, specifically to the lungs.
MATERIALS AND METHODS
Mice and cell cultures
Ten inbred male and female C57BL/6J mice, 12 weeks old, were
grown and maintained in the animal facilities of the Weizmann
Institute of Science and Tel-Aviv University. All animal experi-
ments have been carried out with ethical committee approval. The
ethical guidelines that were followed meet the standards required
by the UKCCCR guidelines (Workman et al, 1998).
The highly metastatic D122 clone of the C57BL/6-derived Lewis
lung carcinoma (Eisenbach et al, 1983) was maintained in DMEM
supplemented with 10% heat-inactivated fetal calf serum, gluta-
mine, combined antibiotics, sodium pyruvate and nonessential
amino acids. The highly metastatic B16-F10.9 clone of the C57BL/
6-derived malignant melanoma (Porgador et al, 1989) was grown
in DMEM supplemented with 10% heat-inactivated fetal calf
serum, glutamine and combined antibiotics.
The mice were divided into four groups. Groups 1 and 2,
consisting of three mice each, male and female, respectively, were
injected intra-footpad with 2 10
5 D122 or B16-F10.9 cells/mouse,
respectively. Groups 3 and 4, consisting of two mice each, male and
female, respectively, served as a control. After 5 weeks, when
primary tumours reached B0.8cm in diameter, animals were
anaesthetized and tumours were dissected and stored at  801C.
After an additional 4 weeks, lungs containing pulmonary
metastases were dissected. The lungs of the mice in the control
groups were dissected at the matching age. All specimens were
snap-frozen in liquid nitrogen.
Preparation of labelled cRNA
Probe preparation was performed as recommended by the
manufacturer of the microarrays (Affymetrix, 1998). Briefly, total
RNA was isolated from pooled primary tumours and pooled lungs
by homogenisation in ice-cold Trizol (Invitrogen). The RNA was
then used as template for double-stranded cDNA synthesis with an
oligo(dT)24 primer containing a T7 RNA polymerase promoter site
added to the 30 end (Genset, La Jolla, CA, USA). The cDNA was
extracted with phenol/chloroform, ethanol-precipitated, and used
as a template for in vitro transcription (Ambion T7 Megascript
system) with biotin-labelled nucleotides (Enzo Diagnostics).
Labelled cRNA was fragmented and a hybridisation mix was
generated as recommended (Affymetrix, 1998).
Hybridisation of microarrays
Aliquots of each sample (10mg cRNA in 200ml hybridisation mix)
were hybridised to a Genechip Hugene FL array. After hybridisa-
tion, each array was washed, stained with streptavidin phycoer-
ythrin (Molecular Probes), washed again, hybridised with biotin
labelled antistreptavidin phycoerythrin antibodies, restained with
streptavidin phycoerythrin (Molecular Probes), and scanned
(Hewlett-Packard, GeneArray scanner G2500A).
Analysis of Genechip data
Scanned output files were visually inspected for hybridisation
artefacts and then analysed using Genechip
s 4.0 software
(Affymetrix). Arrays were scaled to an average intensity of 600
per gene and analysed independently. The expression value for
each gene was determined by calculating the average of differences
(perfect match intensity minus mismatch intensity) of the probe
pairs in use for this gene. The expression analysis files created by
Genechip
s 4.0 software were then transferred to a database
(Microsoft Access) linked to Internet genome databases (e.g.
NHLBI, Swiss Prot and GeneCards) to update gene definitions. A
value of 20 was assigned to all measurements lower than 20. We
did not include in the analysis genes that did not have at least one
average difference intensity value X100 which was defined as
‘present’ call by Affymetrix criteria. For cluster analysis, we used
CLUSTER and TREEVIEW programs described by Eisen et al
(1998). Fold ratios were calculated for each primary tumour
against the pulmonary metastases of the same model and for the
pulmonary metastases against the normal lung of the same gender.
To ensure that the enhanced expression of genes in the pulmonary
metastases was not due solely to the influence of the microenvir-
onment, we removed genes with a higher level of expression in the
normal murine lung compared to the pulmonary metastases. This
criterion filtered 55, 78 and 91% of the genes that were otherwise
considered as overexpressed in the D122, B16-F10.9 and both
models, respectively.
Real-time quantitative PCR analysis
Relative quantitative PCR was performed using the LightCycler
System
s (Roche Diagnostics). An aliquot of 6mg of the previously
extracted total RNA was reverse transcribed using Moloney
Murine Leukemia Virus-Reverse Transcriptase (RT) and random
hexamers as primer (Promega). The obtained cDNA was diluted
1/10 with water and 5ml was used for amplification. The PCR was
performed with the LightCycler FastStart DNA SYBR GreenI Kit
(Roche Diagnostics) according to the protocol provided in the kit.
To control for specificity of the amplification products, a melting
curve analysis was performed. No amplification of unspecific
products was observed. In addition, PCR products were gel
separated to confirm a band of the expected size.
The relative initial amount of cDNA of a particular template in
the cDNA mixture was extrapolated from a standard curve. The
standards, composed of five serial dilutions of one of the cDNAs,
ranging from 1/5 to 1/1000 of the original cDNA, were run in
parallel with the samples under identical PCR conditions,
amplified with the same set of primers. The slope of the standard
curve was converted to the amplification efficiency E by the
following algorithm: E¼10
 1/slope. The primers used for all four
genes – PAI-2, RhoC, WISP-1 and UG had an efficiency 41.85
(data not shown). The relative amounts obtained were normalised
by the housekeeping gene beta-actin, whose levels of expression
were not changed significantly according to the microarrays (data
not shown). The detailed procedure for quantification has been
described by Ginzinger (2002).
The primer sequences were (50 to 30):
beta-actin – CTGAGAGGGAAATCGTGCG, GGTGGTACCACCA
GACAAC;
PAI-2 – CTGCTACCCGAAGGTTCTG, GGAAGCAACAGGAG
CATGC;
RhoC – GCTGGGCAAGAAGACTACG, CCTTCCTCAGATCGA
ACCG;
WISP-1 – CGTGGAGCAACGGTATGAG, GAGAGTGAAGTTCG
TGGCC;
UG – CATGCTGTCCATCTGCTGC, CTCTTGTGGGAGGGTATCC.
RESULTS
Global analysis of gene expression
Global analysis of gene expression reveals a correlation between
the primary tumour of each model, D122 or B16-F10.9, to its
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smatching pulmonary metastases. In other words, as expected, the
diversity between the two models is greater than the diversity
between the primary tumour and the pulmonary metastases of the
same model. Only genes with at least one average difference
intensity value X100, which are defined as ‘present’ by Affymetrix
criteria, were included in the cluster analysis (Figure 1).
Oligonucleotide microarray analysis
The tumour model described above was used with the highly
metastatic mouse D122 Lewis lung carcinoma and B16-F10.9
melanoma cell lines. Microarray experiments examined differences
in gene expressions between the subcutaneous primary tumour
and the pulmonary metastases. We focus on the genes that were
overexpressed in the pulmonary metastases compared to the
primary tumour, since we assume that transcripts overexpressed in
metastatic tissue have applicable diagnostic and therapeutic
potential. Forty-two and 16 genes were overexpressed in pulmon-
ary metastases derived from the mouse D122 and B16-F10.9 cell
lines, respectively (Tables 1a and b). Seven genes, namely –
arginase, brain natriuretic peptide (BNP), interleukin-1 alpha (IL-1
alpha), plasminogen activator inhibitor-2 (PAI-2), surfactant
protein C (SP-C), uteroglobin (UG) and wnt-1-induced secreted
protein-1 (WISP-1), were overexpressed in pulmonary metastases
of both cell lines (Table 2).
We could not detect any consistent difference in the expression
of RhoC in pulmonary metastases compared to the primary
tumour. As this gene has been previously shown to be important in
the metastatic phenotype of melanoma cell lines (Clark et al, 2000),
we confirmed this microarray result using real-time quantitative
PCR (RTQ–PCR) (Figure 2).
RTQ–PCR confirms overexpression of PAI-2, WISP-1 and
UG in pulmonary metastases of both cell lines
To further investigate the reliability of our array data, we measured
the expression levels of PAI-2, WISP-1 and UG that were
overexpressed in both models using the LightCycler System
s
(Roche Diagnostics). The expression levels of PAI-2, WISP-1 and
UG measured by RTQ–PCR were similar to those measured by the
microarrays (Figure 3, UG data not shown).
DISCUSSION
Previous studies provided insight into the patterns of gene
expression that allow tumours to metastasise by comparing highly
Figure 1 Dendrogram of cluster analysis of microarrays. CL, normal
male murine lung – Control for the D122 Lewis lung model; CM, normal
female murine lung – control for the B16-F10.9 melanoma model; ML –
pulmonary metastases of the D122 Lewis lung model; PL – primary tumour
of the D122 Lewis lung model; MM – pulmonary metastases of the B16-
F10.9 melanoma model; PM – primary tumour of the B 16-F10.9
melanoma model.
Table 1 Functional groups of genes that were overexpressed, at a fold
X2.5, in pulmonary metastases compared to primary tumour in the (a)
D122 model and (b) B16-F10.9 model
Description
GenBank
accession #
Fold
ratio
(a) D122 model
Apoptosis
Caspase 3
a U54803 2.9
miap-3 U88990 3.0
MIHA U36842 7.1
Cell adhesion
Integrin alpha V (Cd51)
a U14135 2.9
Islr AB024538 5.2
Lymphocyte antigen 84
a Y07519 2.6
Cellular matrix
Actin, alpha 1 M12347 5.5
histone H2a(A)-613, H2a(B)-613 and H2b-613 (H2b) U62673 4.1
Differentiation
H19 X58196 3.0
Madr2 U60530 2.7
ECM/angiogenesis
Collagen type VI, alpha 3 subunit AF064749 9.7
Enamelin U82698 10.1
Fibronectin M18194 4.5
Matrilin-2 precursor
a U69262 4.0
Procollagen type X, alpha 1 X67348 3.8
Membrane and nuclear membrane
YE1/48 M25775 3.1
Metabolism
Acetyl coenzyme A dehydrogenase, long-chain
a U21489 2.6
AKR1C13 AB027125 9.7
Ferrochelatase M61215 3.0
griPGHS
a M88242 6.3
Pex U75646 4.4
Receptors/ligands
Bacteria binding macrophage receptor MARCO U18424 7.4
GRIP1 U39060 6.4
MIP2 X53798 7.9
Signal transduction
Mess1
a U28726 14.5
MPA X60664 2.5
WSB-2 AF033188 2.6
Transcription
mafF
a AB009694 10.9
Slug, chicken homologue U79550 2.5
zinc finger gene OZF
a AJ224763 5.8
Translation
N-myristoyltransferase 2
a AF043327 10.8
Ribosomal protein (Rpl12) L04280 2.8
Other
Dnmt2
a AF012129 2.8
homer-2a AF093259 3.7
Lysophospholipase I U89352 10.4
Modifier 2 protein
a X56683 2.5
P35B
a X53619 2.6
PLA2 M72394 2.6
Retinaldehyde-binding protein AF084642 4.9
SCID complementing gene 2
a D78188 3.6
Sfrp2 U88567 6.8
Synaptobrevin-like protein X96737 3.1
(b) B16-F10.9 model
Apoptosis
P53-variant
b U59758 3.9
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smetastatic vs low metastatic cell lines. This approach identified
genes that were overexpressed within the highly metastatic cell line
and that were, in general, essential to the nonmetastatic/metastatic
switch. One study using this approach demonstrated that the small
GTPase RhoC was essential for the enhancement of melanoma
metastasis when overexpressed. Furthermore, analysis of the
phenotype of melanoma cells expressing dominant-negative Rho
or RhoC indicated that RhoC is important in tumour cell invasion
(Clark et al, 2000).
In this study, we could identify essential targets expressed within
the tumour cell, as a result of interactions with the surrounding
microenvironment. The reason for this is the comparison made
between two phases of a tumour progression in vivo – the primary
site and the metastases, both with the surrounding tissue,
originating from a highly metastatic cell line. Our attitude aimed
to emphasise genes that could be essential for metastasis to the
lungs and might play a key role in homing the tumour cells
specifically to that organ. Therefore, in our study, the small
GTPase RhoC was not overexpressed in the pulmonary metastases
compared to the primary tumour of both cell lines. We therefore
argue that RhoC has general importance in tumour invasiveness
and in the nonmetatstatic/metastatic switch, but not in the specific
metastatic homing to the lungs.
Previously, Gemma et al (2001) compared the expression
profiles of two subpopulations of an adenocarcinoma cell line
with high metastatic potential – PC9/f9 and PC9/f14 – with the
parent cell line PC9 using cDNA array. They have shown that the
expression of matrix metalloproteinase-2 (MMP-2), plasminogen
activator inhibitor-1 (PAI-1) and IL-1 alpha was overexpressed in
the highly metastatic subpopulations. There is already abundant
experimental evidence that the plasminogen activator system plays
a key role in tumour invasion and metastasis (Andreasen et al,
1997; Schmitt et al, 1997). A critical balance of uPA, its cell surface
receptor uPA-R (CD 87), and its inhibitor PAI-1 is the prerequisite
for efficient focal proteolysis, adhesion and migration, and hence,
subsequent tumour cell invasion and metastasis. There is evidence
that PAI-2 may block uPA-mediated proteolysis and is inversely
correlated with tumour progression of nonsmall cell lung
carcinomas and neuroendocrine lung tumours (Robert et al,
1999) and breast cancer (Borstnar et al, 2002). In contrast, higher
expression levels of PAI-2 were found in tumour tissues as
compared to their normal equivalents and significant relations
were found between PAI-2 and pathological stage in nonsmall cell
lung cancer patients (Salden et al, 2000). Our data suggest a key
role for PAI-2 in lung metastasis from different tumour origins.
Wnt-1-induced secreted protein (WISP-1) was identified by
Pennica et al (1998) as an oncogene regulated by the Wnt-1-beta-
catenin pathway and is a member of the CCN family of growth
factors, which are cysteine-rich, heparin-binding, secreted proteins
associated with the extracellular matrix, and can interact with
ECM/angiogenesis
Hyaluronidase 1 AF011567 5.8
Minopontin X13986 8.7
VEGF-C U73620 4.6
Metabolism/proteosome
beta-TrCP protein E3RS Ikappa B
b AF099932 7.9
Ceramide glucosyltransferase D89866 15.0
Signal transduction
cAMP-dependent Rap 1 AF115480 6.3
LIM and SH3 protein 1 U58882 5.2
RAB7, member RAS oncogene familly Y13361 2.8
Receptors/ligands
Mouse homologue of human ocular albinism 1 X98352 2.7
Transcription/translation
Cyclin T1
b AF095640 3.5
Myeloblastosis oncogene-like 1 L35261 2.9
Zinc-finger protein 40 D10632 5.1
Other
HSP-105 L40406 2.5
Mouse Ig kappa chain V-region M18237 16.5
Potassium channel alpha subunit
b AF008574 2.9
aIndicates genes that were underexpressed in the B16-F10.9 model.
bIndicates genes
that were underexpressed in the D122 model. Genes that were overexpressed in
both models are not shown.
Table 1 Continued
Description
GenBank
accession #
Fold
ratio
Table 2 Genes that were overexpressed, at a fold X2.5, in pulmonary
metastases compared to primary tumour in both D122 and B16-F10.9
models
GenBank
Fold ratio
Description accession # D122 model F10.9 model
Arginase U51805 22.5 4.9
BNP D16497 2.7 2.7
IL-1 alpha M14639 3.1 7.9
PAI-2 X16490 4.4 2.5
SP-C AA921489 239.3 102.5
UG L04503 383.6 27.7
WISP-1 AF100777 3.7 4.5
D122, Microarray
D122, RTQ_PCR
F10.9, Microarray
F10.9, RTQ_PCR
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Figure 2 Comparative ratio analysis by RTQ–PCR and microarrays.
Fold ratios were calculated for each primary tumour against the pulmonary
metastases. RTQ–PCR results (mean7s.d.) were obtained from three
independent experiments, each in duplicate.
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Figure 3 Comparative ratio analysis by RTQ–PCR and microarrays.
Fold ratios were calculated for each primary tumour against the pulmonary
metastases. RTQ–PCR results (mean7s.d.) for WISP-1 and PAI-2
were obtained from three and four independent experiments, respectively,
each in duplicate (PAI-2 results are illustrated by two representative
experiments).
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scellular integrins. Xu et al (2000) identified WISP-1 as beta-
catenin-regulated and its forced overexpression in normal rat
kidney fibroblasts (NRK-49F) was sufficient to induce their
transformation. Recently, it was shown that WISP-1 can both
activate the anti-apoptotic Akt/PKB signalling pathway and act to
block cell death in the p53-mediated apoptosis pathway (Su et al,
2002).
Wnt-1-induced secreted protein-1 was overexpressed (2 to
425-fold) in 84% of human colon tumours examined compared
with patient-matched normal adjacent mucosa (Pennica et al,
1998). The expression levels of WISP-1, in mammary tumours
from Wnt-1 transgenic mice, were high in stromal fibroblasts lying
within the fibrovascular tumour stroma, but low focally within
tumour cells (Pennica et al, 1998). Elevated levels of WISP-1 in
primary breast cancer were associated with more advanced
features, such as tumour size and metastases to axillary lymph
nodes (Xie et al, 2001).
In contrast, WISP-1 was found to be one of the 70 prognostic
reporter genes able to identify clinical outcome in primary breast
cancer patients. It was shown that WISP-1 was overexpressed in
the good prognosis group of patients, who did not develop distant
metastases within 5 years (Van’t Veer et al, 2002). Furthermore,
the mouse WISP-1 is identical to the gene identified as ELM1
(GenBank accession# AB004873). ELM1 is expressed in low, but
not high, metastatic mouse melanoma cells, and suppresses the in
vivo growth and metastatic potential of K-1735 mouse melanoma
cells (Hashimoto et al, 1998). The contradiction between the above
findings may be explained in view of previous studies suggesting
that the effect of a single gene may differ according to the genetic
and cellular context. For example, c-MYC can induce both cell
proliferation and apoptosis (Evan et al, 1992; Jain et al, 2002;
Pelengaris et al, 2002). Another example was given by Serrano et al
(1997), who showed that the oncogene ras, known for its ability to
transform immortal rodent cells to a tumourigenic state, can
provoke premature cell senescence in primary human and rodent
cells.
Here we have demonstrated overexpression of WISP-1 in
pulmonary metastases of two distinct metastatic cell lines. We
propose a key role for WISP-1 in the metastasising process to the
lungs.
Interleukin-1 alpha was shown to enhance the adhesion of A549
lung carcinoma and M6 melanoma cells to the vascular surface
both in vitro and in vivo, suggesting that IL-1 proteins facilitate the
metastatic process (Lauri et al, 1990). Significant correlation
between expression of IL-1 alpha and liver metastasis in gastric
carcinoma was shown (Tomimatsu et al, 2001), suggesting that
IL-1 alpha functions universally in the metastatic process. Here
we have demonstrated overexpression of IL-1 alpha in pulmonary
metastases of two distinct metastatic cell lines.
Arginase converts L-arginine to L-ornithine, which is the
precursor of polyamines that are essential components of cell
proliferation. N-hydroxy-L-arginine (NOHA), a stable intermediate
product formed during conversion of L-arginine to NO by nitric
oxide synthase, inhibited proliferation of the high arginase-
expressing MDA-MB-468 cells, activated caspase-3 and induced
apoptosis after 48h (Singh et al, 2000). Additionally, Chang et al
(2001) have shown that arginase induction in macrophages can
enhance tumour cell growth by providing them with polyamines
and suppress tumour cytotoxicity by reducing NO production. The
arginase inhibitor L-norvaline downregulated this proliferative
effect. Yet, an active subunit of arginase was found to inhibit
differentially poorly liver metastasizing cell lines (Cavanaugh and
Nicolson, 2000). Highly metastatic cells displayed no ability to
preferentially inactivate or inhibit the activity of arginase, but they
did display slightly greater amounts of intracellular arginine. Here,
however, arginase was overexpressed in pulmonary metastases of
two distinct metastatic cell lines. Therefore, arginase may be
essential for tumour metastasis to the lungs, but not to the liver,
and lung macrophages might take part in that process.
Brain natriuretic peptide (BNP) is a polypeptide hormone,
demonstrated mainly in the heart, which causes vasodilation and
natriuresis in man and animals. Elevated levels of BNP are usually
associated with cardiac dysfunction (Cowie and Mendez, 2002).
There is also evidence that human small cell lung cancer cell lines
produce BNP (Ohsaki et al, 1999). There is no known connection
of BNP to tumourigenesis or metastasis.
Uteroglobin (UG) was found to be infrequently expressed in
non-small cell lung cancer cell lines, despite being abundantly
produced by progenitor cells for normal and neoplastic airway
epithelium. A549 cells transfected with UG demonstrated a marked
reduction in invasiveness and decreased adhesiveness to fibro-
nectin compared with the controls (Szabo et al, 1998). Surfactant-C
(SP-C) is overexpressed in normal lungs and plays an important
role in its functioning. Our data show overexpression of UG and
SP-C in pulmonary metastases compared to both primary tumours
and normal lung. Nevertheless, these genes were also over-
expressed in the normal lung compared to the primary tumour.
Most of the previously described genetic alterations in various
cancers involve inactivation of tumour suppressor genes. The
proteins produced from these genes are difficult to target with
drugs, because they are inactive or absent in the cancer cells. In
contrast, enzymes whose expression is elevated in cancer cells like
those encoded by WISP-1, arginase, IL-1 alpha and PAI-2 provide
excellent targets for drug discovery purposes. Further research
should address the specific role of these genes in the formation of
pulmonary metastases from different tumours.
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